Oral Oncology Reports最新文献

Low-grade mucoepidermoid carcinoma (MEC) is a salivary gland tumor arising rarely within the jaw bones. It poses a diagnostic challenge due to its considerable overlap of the histopathological features with Glandular odontogenic cyst (GOC). Various theories have been put forward to explain the origin of central low-grade MEC, one of the potential being MEC arising from the lining of GOC. In the present paper we report a case of a multilocular lesion in a 54-year-old female in the mandibular anterior region, which clinically and microscopically had a resemblance to the glandular odontogenic cyst, but the final diagnosis of low-grade MEC was confirmed based on the immunohistochemical appraisal.

Objectives

There is a limited number of updated epidemiological Brazilian data on head and neck squamous cell carcinoma (HNSCC). This study aimed to describe demographic and clinical characteristics of HNSCC patients from Brazilian public and private systems.

Methods

This is a retrospective observational study that included patients diagnosed with HNSCC from Brazilian public and private settings from 2016 to 2018. As for the public scenario, data were drawn from the public hospital national cancer registry database. As for the private sector, the data were extracted from medical records of patients from Oncoclinicas, a large Brazilian oncology group.

Results

A total of 37,121 patients were included in the study, with 36,914 from the public and 207 from the private system. Patients in the public sector were younger than those in the private sector, with medians ages of 61.2 and 66.9 years, respectively. In both cohorts, a predominance of men with a history of tobacco and alcohol consumption and an advanced locoregional stage at diagnosis was observed. The main site of the primary tumor was the oropharynx in the private sector and oral cavity in the public sector. Among patients with oropharyngeal cancer, only those in the private sector were tested for HPV, with the majority being positive.

Conclusions

This real-world data study provides epidemiologic characteristics of patients with HNSCC in two different Brazilian healthcare settings, presenting relevant insights into possible opportunities for improvements in the patient's journey with HNSCC.

Background

Oral second primary tumours (SPTs) have a poor prognosis due to late-stage diagnosis. This study evaluates the demographic and clinicopathological risk predictors of SPTs.

Methods

Patients with oral squamous cell carcinoma, carcinoma in situ, or severe dysplasia were accrued into the Oral Cancer Prediction Longitudinal study within one year post-curative treatment. Data on demographics, risk habits, and primary tumour characteristics were collected. Clinical follow-up included assessing the presence of second oral premalignant lesions (SOPLs), clinicopathological features, and the results from toluidine blue staining and fluorescence visualization.

Results

Among 296 patients, 23 (8 %) developed SPTs. Older age at primary cancer diagnosis (P = 0.008) and a history of chewing tobacco or betel nut (P = 0.043) increased the risk of SPTs. Patients with primary tumours located at low-risk sites had an increased risk of SPTs (P = 0.004), which often presented at high-risk sites. The presence of SOPLs (P < 0.001), and multiple lesions (P = 0.017) significantly increased the risk of SPTs. Positive toluidine blue staining indicated a trend toward higher risk of SPTs, whereas fluorescence visualization did not. The median time to SPT diagnosis was 3.25 years post-treatment.

Conclusions

Identifying second or multiple oral premalignant lesions is critical for predicting the risk of SPTs regardless of their clinical or histological characteristics. Routine biopsy of these lesions should be prioritized to ensure timely diagnosis. Incorporating these risk predictors into clinical follow-up can enhance early cancer detection and improve patient outcomes.

This comprehensive review explores the potential of nanotherapy in the treatment of blood cancers, specifically leukemia, lymphoma, and myeloma, in the oral cavity. Nanoparticles (NPs) made from organic and inorganic materials have shown promise in delivering therapeutic substances to cancer cells, enhancing their pharmacological efficacy, and reducing their systemic toxicity. Different types of nanoparticles, such as liposomes, extracellular vehicles, and polymeric nanoparticles, have been studied for their effectiveness in targeting cancer cells. Nanotherapy has also been investigated for overcoming drug resistance, targeting cancer stem cells, bypassing efflux pumps, and gene silencing. Clinical trials and research findings have demonstrated the potential of nanotherapy for improving outcomes in patients with acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. However, challenges exist in addressing the heterogeneity of blood cancers in the oral cavity, navigating the tumor microenvironment, overcoming drug resistance, and modulating immune evasion. Future directions include individualized treatment plans, multifunctional nanoparticles, combination therapies, and improved nanoparticle design. The translation of these breakthroughs into clinical practice requires collaboration among researchers, physicians, and industry stakeholders. Overall, nanotherapy holds promise for more effective and less invasive treatments for blood cancer in the oral cavity.

The pathogenesis of membranous BCA recurrence remains unclear, with only a few cases reported. The current study focuses on a case that exhibits a high Ki-67 proliferative index, which raises questions about its impact on the prognosis and treatment plan. We have conducted a literature review to gain insight into the altered ki67 expression pattern in membranous BCA. We have also proposed a hypothesis that suggests recurrent membranous BCA cases with Ki67 levels between 5 % and 10 % signify an intermediate grade and warrant reclassification. More research is needed to confirm this hypothesis and understand the prognosis for this variant.

Background

pl6 (CDKN2a) play a role in tumorigenesis in some head and neck squamous cell carcinomas. Frequent homozygous deletions of the pl6 gene have been reported in many tumor cell lines including the brain, breast, osteosarcomas, melanomas, kidney, bladder, and ovary.

Materials and methods

5 patients without any tobacco using habit were included in group I as controls. 10 clinically and histopathologically confirmed cases of oral potentially malignant disorders (OPMDs) [oral submucous fibrosis (OSMF) −7 & leukoplakia (moderate dysplasia) −3] were included in group II. 10 clinically and histopathologically confirmed cases of OSCC were categorized as group III. Buccal scrapings were taken and analyzed for exon 1, 2, 3 of p16 and homozygous deletion in exon 2 of p16 was also detected by PCR and gel electrophoresis.

Results

PCR amplification products of exon 1, 2, 3 of p16 were found in all 25 samples which include 10 cases of OSCC, 10 cases of OPMDs and 5 controls. Homozygous deletion in exon 2 was found only in 30 % of OSCC and 20 % of OPMD.

Conclusion

Our study showed that cytological samples yield sufficient amount of DNA, which showed 100 % positivity with exon 1, 2, 3 of p16 gene, but the percentage of genetic alteration of p16 gene seems to be less when compared with other related studies.